SCHEMBL274702

SCHEMBL274702

O=Cc1cc(F)ccc1Oc1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
GAA P10253 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 6/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.47
HSPB1 P04792 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
MAP2K1 Q02750 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
EPAS1 Q99814 1/20 0.44
PTGER4 P35408 1/20 0.41
PTGER2 P43116 1/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437574 0.90 KMT2A (0.46) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL275895 0.90 ALDH1A1 (0.66) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL16110966 0.89 LMNA (0.68) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL19563733 0.86 EPAS1 (0.49) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL274863 0.86 PTGDR2 (0.48) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL18570918 0.86 SCN8A (0.48) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL18570387 0.86 SCN8A (0.48) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL18570379 0.86 CACNA1C (0.50) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL276089 0.86 TBXA2R (0.45) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL2558181 0.86 PARP10 (0.57) LMNAGAAKMT2AALDH1A1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT LMNA 549/4885GAA 1785/4885KMT2A 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.